Veradermics, Inc
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During our fiscal quarter ended September 30, 2026, certain of our directors or “officers,” (as defined in Rule 16a-1(f) under the Exchange Act) entered into a contract, instruction or written plan for the purchase or sale of our securities that is intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information. We refer to these contracts, instructions, and written plans as “Rule 10b5-1 trading plans” and each one as a “Rule 10b5-1 trading plan.”
We describe the material terms of these Rule 10b5-1 trading plans in the table below.
Rule 10b5-1 Trading Plans
| Director/Officer | Action and Date of Action | Commencement of Trading Period | Scheduled Termination of Trading Period (1) | Security Covered | Maximum Number of Securities to be Purchased or Sold Pursuant to the Rule 10b5-1 Trading Plan (2) | Covers Purchase or Sale |
|---|---|---|---|---|---|---|
| Mark Neumann | Adoption 08/13/2026 | 12/2/2026 | 12/3/2027 | Common Stock | 80,000 | Sale |
| Dominic Carrano | Adoption 09/21/2026 | 12/21/2026 | 12/22/2027 | Common Stock | 42,000 | Sale |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.